238 related articles for article (PubMed ID: 19322169)
1. Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol.
Wise LE; Thorpe AJ; Lichtman AH
Neuropsychopharmacology; 2009 Aug; 34(9):2072-80. PubMed ID: 19322169
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
3. Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats.
Robinson L; McKillop-Smith S; Ross NL; Pertwee RG; Hampson RE; Platt B; Riedel G
Psychopharmacology (Berl); 2008 Jul; 198(4):551-63. PubMed ID: 18049812
[TBL] [Abstract][Full Text] [Related]
4. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats.
Lichtman AH; Dimen KR; Martin BR
Psychopharmacology (Berl); 1995 Jun; 119(3):282-90. PubMed ID: 7675962
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
DeLong GT; Wolf CE; Poklis A; Lichtman AH
Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971
[TBL] [Abstract][Full Text] [Related]
7. Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze.
Nava F; Carta G; Colombo G; Gessa GL
Neuropharmacology; 2001 Sep; 41(3):392-9. PubMed ID: 11522331
[TBL] [Abstract][Full Text] [Related]
8. Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.
Sousa VC; Assaife-Lopes N; Ribeiro JA; Pratt JA; Brett RR; Sebastião AM
Neuropsychopharmacology; 2011 Jan; 36(2):472-87. PubMed ID: 20927050
[TBL] [Abstract][Full Text] [Related]
9. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism.
Lichtman AH; Martin BR
Psychopharmacology (Berl); 1996 Jul; 126(2):125-31. PubMed ID: 8856831
[TBL] [Abstract][Full Text] [Related]
10. delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.
Wise LE; Varvel SA; Selley DE; Wiebelhaus JM; Long KA; Middleton LS; Sim-Selley LJ; Lichtman AH
Psychopharmacology (Berl); 2011 Oct; 217(4):485-94. PubMed ID: 21559804
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats.
Hampson RE; Deadwyler SA
J Neurosci; 2000 Dec; 20(23):8932-42. PubMed ID: 11102504
[TBL] [Abstract][Full Text] [Related]
12. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
Lichtman AH; Martin BR
Pharmacol Biochem Behav; 1997; 57(1-2):7-12. PubMed ID: 9164547
[TBL] [Abstract][Full Text] [Related]
13. The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats.
Robinson L; Goonawardena AV; Pertwee RG; Hampson RE; Riedel G
Br J Pharmacol; 2007 Jul; 151(5):688-700. PubMed ID: 17502849
[TBL] [Abstract][Full Text] [Related]
14. Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle.
Wiley JL; Matthew Walentiny D; Vann RE; Baskfield CY
Behav Pharmacol; 2011 Sep; 22(5-6):480-8. PubMed ID: 21712709
[TBL] [Abstract][Full Text] [Related]
15. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ
Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Li F; Fang Q; Liu Y; Zhao M; Li D; Wang J; Lu L
Eur J Pharmacol; 2008 Jul; 589(1-3):122-6. PubMed ID: 18534572
[TBL] [Abstract][Full Text] [Related]
19. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
20. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
McMahon LR
Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
